EITVent-2 — Study and Centre Participation Overview

Source: EITVent-2 investigator manual, version 10 June 2026.
This website summary does not replace the full protocol, ethics documents or formal centre eligibility requirements.

STUDY
A multicentre, randomised, open-label trial with a Bayesian adaptive enrichment design, evaluating EIT-guided PEEP titration versus a low PEEP/FiO2 table strategy in mechanically ventilated patients with moderate-to-severe ARDS.
Principal investigator: Prof. Ling Liu.
Protocol identifier listed in the manual: NCT06990477.
ClinicalTrials.gov record: https://clinicaltrials.gov/study/NCT06990477

RESEARCH QUESTION
Do the clinical effects of EIT-guided PEEP differ by lung recruitability? Clinical benefit remains a research hypothesis, not an established result or a promise of benefit to an individual patient.

DESIGN
Up to 2,400 participants: a planned upper limit, not current enrolment.
All enrolled patients receive an EIT assessment before randomisation. Randomisation is stratified by centre and alveolar collapse percentage, using a 25% threshold, with 1:1 allocation.
Primary outcome: 28-day mortality.
Secondary outcomes include 60-day mortality, ventilator-free days through day 28, and other ICU and hospital outcomes. Follow-up outcome collection extends to day 60.

INCLUSION CRITERIA
1. Age 18–85 years.
2. Moderate-to-severe ARDS according to the Berlin definition: within 24 hours before screening, PaO2/FiO2 ≤ 200 mmHg at PEEP ≥ 5 cmH2O.
3. ARDS diagnosed within the preceding 72 hours.
All exclusion criteria must also be assessed, and an appropriate informed-consent process completed by the research team.

CENTRE DISCUSSION CHECKLIST (SUGGESTED)
- Hospital and ICU overview, relevant patient population and proposed research contact.
- Available EIT equipment and staff experience.
- Research staffing, protocol delivery, data recording and follow-up arrangements.
- Formal centre requirements, training, ethics procedures and study initiation to be confirmed with the research team.
This is a communication checklist, not an official centre eligibility standard.

CONTACT
Contact: yuanxueyan1991@gmail.com or liulingdoctor@126.com. Please do not include identifiable patient information in email enquiries.
Current recruitment status, centre participation and formal study documents should be confirmed with the research team.